Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effects of COVID-19 on training within urology: Lessons learned in virtual learning, human factors, non-technical skills and reflective practice.

Journal of clinical urology·2024
Same author

Telogen effluvium and COVID-19: a cross-sectional study.

European review for medical and pharmacological sciences·2023
Same author

Experimental platforms to study blast injury.

Journal of the Royal Army Medical Corps·2018
Same author

The Use of Antibiotics in Gynecological Endoscopy. A Randomized, Double-Blind, Placebo-Controlled Trial.

Journal of minimally invasive gynecology·2016
Same author

Anabolic androgenic steroids, an easily forgotten cause of polycythaemia and cerebral infarction.

Internal medicine journal·2016
Same author

The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock.

Oncogenesis·2016
Same journal

The paradox of peer review: protecting science or policing thought?

Internal medicine journal·2026
Same journal

Immune-related pancytopenia in pregnancy.

Internal medicine journal·2026
Same journal

Crossover effect: causal machine learning reveals opposing mortality responses to mean arterial pressure targets among phenotypically distinct hypertensive patients with septic shock.

Internal medicine journal·2026
Same journal

Clinicopathological findings, correlations and outcomes in patients with renal disease and living with antiretroviral-treated human immunodeficiency virus infection.

Internal medicine journal·2026
Same journal

Approach to thyroid disorders associated with immune checkpoint inhibitors and tyrosine kinase inhibitors.

Internal medicine journal·2026
Same journal

A scoping review of specialist hypertension clinics.

Internal medicine journal·2026
See all related articles

Related Experiment Video

Updated: Jun 8, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Acquired factor V inhibitor

P P G Teh, G Grigoriadis, H Salem

    Internal Medicine Journal
    |September 16, 2010
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
    08:13

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

    Published on: September 30, 2021

    Related Experiment Videos

    Last Updated: Jun 8, 2026

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
    13:08

    Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

    Published on: September 9, 2012

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
    08:13

    Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

    Published on: September 30, 2021